Restoration of fibroblast growth factor receptor 2IIIb enhances the chemosensitivity of human prostate cancer cells

Shoji,Koichi; Teishima,Jun; Hayashi,Tetsutaro; Ohara,Shinya; Mckeehan,Wallace L.; Matsubara,Akio

doi:10.3892/or.2014.3200

Restoration of fibroblast growth factor receptor 2IIIb enhances the chemosensitivity of human prostate cancer cells

Authors:
- Koichi Shoji
- Jun Teishima
- Tetsutaro Hayashi
- Shinya Ohara
- Wallace L. Mckeehan
- Akio Matsubara
View Affiliations

Affiliations: Department of Urology, Institute of Biomedical and Health Sciences, Integrated Health Science, Hiroshima University, Hiroshima 734-8551, Japan, Center for Cancer and Stem Cell Biology, Institute of Bioscience and Technology, Texas A&M Health Science Center, Houston, TX 77030, USA
Published online on: May 20, 2014 https://doi.org/10.3892/or.2014.3200
Pages: 65-70

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fibroblast growth factor receptor 2 (FGFR2) is thought to mediate an important signaling pathway between prostate epithelial cells and stromal cells for maintenance of homeostasis in normal prostate tissue. Abnormalities of FGFR2 have been shown in advanced prostate cancer or prostate cancer cell lines, and we previously demonstrated the tumor-suppressive effects of the restoration of FGFR2IIIb in prostate cancer cells. The aim of the present study was to determine whether FGFR2IIIb plays a role in the chemosensitivity of castration-resistant prostate cancer cells. A clonal line of PC-3 cells expressing FGFR2IIIb (PC-3R2IIIb) was established by transfection with an IRESneo2-expressing vector bearing FGFR2IIIb cDNA. The effects of chemotherapeutic agents (docetaxel, cisplatin, 5-fluorouracil and zoledronic acid) on cell viability and apoptosis were examined by MTT assay and western blot analysis, respectively. Expression levels of molecules that were markers of epithelial-to-mesenchymal transition and chemosensitivity-related proteins were assessed by western blot analysis. Viability of the PC-3R2IIIb cells was significantly lower than that of the control PC-3 cells transfected with the vector alone (PC-3neo), and viability was further suppressed by treatment with chemotherapeutic agents, particularly docetaxel. Induced expression of caspase-3 was evident in the PC-3R2IIIb cells and was further enhanced by treatment with docetaxel. Expression of N-cadherin, vimentin, survivin and XIAP was lower in the PC-3R2IIIb cells than that in the PC-3neo cells. In contrast, expression of p21 was higher in the PC-3R2IIIb cells than that in the control PC-3neo cells. These data indicate that restoration of FGFR2IIIb in castration-resistant prostate cancer cells may reverse some of the epithelial-to-mesenchymal cell properties characteristic of tumor cells and induce in part mesenchymal-to-epithelial transition properties. This together with enhancement of apoptotic pathways involving caspase-3 may enhance chemosensitivity particularly to docetaxel which is widely used in the treatment of castration-resistant prostate cancer.

View Figures

View References

1	Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66. 2007. View Article : Google Scholar
2	Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin. 56:106–130. 2006. View Article : Google Scholar
3	Nakata S, Takahashi H, Ohtake N, Takei T and Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 7:254–257. 2000. View Article : Google Scholar : PubMed/NCBI
4	Kirby R, Christmas T and Brawer M: Management of metastatic disease. Prostate Cancer. Hamilton L: Mosby-Year Book, Inc; St. Louis, MO: pp. 129–141. 1996
5	Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI
6	Lu W, Luo Y, Kan M and McKeehan WL: Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate. J Biol Chem. 274:12827–12834. 1999. View Article : Google Scholar : PubMed/NCBI
7	Sugimura Y, Foster BA, Hom YK, et al: Keratinocyte growth factor (KGF) can replace testosterone in the ductal branching morphogenesis of the rat ventral prostate. Int J Dev Biol. 40:941–951. 1996.PubMed/NCBI
8	Nakano K, Fukabori Y, Itoh N, et al: Androgen-stimulated human prostate epithelial growth mediated by stromal-derived fibroblast growth factor-10. Endocr J. 46:405–413. 1999. View Article : Google Scholar : PubMed/NCBI
9	Yan G, Fukabori Y, McBride G, Nikolaropolous S and McKeehan WL: Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol. 13:4513–4522. 1993.
10	Naimi B, Latil A, Fournier G, Mangin P, Cussenot O and Berthon P: Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate. Prostate. 52:245–252. 2002. View Article : Google Scholar : PubMed/NCBI
11	Carstens RP, Eaton JV, Krigman HR, Walther PJ and Garcia-Blanco MA: Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer. Oncogene. 15:3059–3065. 1997. View Article : Google Scholar : PubMed/NCBI
12	Werner S, Duan DS, de Vries C, Peters KG, Johnson DE and Williams LT: Differential splicing in the extracellular region of fibroblast growth factor receptor 1 generates receptor variants with different ligand-binding specificities. Mol Cell Biol. 12:82–88. 1992.
13	Kan M, Uematsu F, Wu X and Wang F: Directional specificity of prostate stromal to epithelial cell communication via FGF7/FGFR2 is set by cell- and FGFR2 isoform-specific heparan sulfate. In Vitro Cell Dev Biol Anim. 37:575–577. 2001. View Article : Google Scholar : PubMed/NCBI
14	Yan G, Fukabori Y, Nikolaropoulos S, Wang F and McKeehan WL: Heparin-binding keratinocyte growth factor is a candidate stromal-to-epithelial-cell andromedin. Mol Endocrinol. 6:2123–2128. 1992.PubMed/NCBI
15	Kwabi-Addo B, Ozen M and Ittmann M: The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer. 11:709–724. 2004. View Article : Google Scholar : PubMed/NCBI
16	Fukabori Y, Yan G, Yamanaka H and McKeehan WL: Rapid induction of keratinocyte growth factor (FGF-7) and beta-actin after exposure of prostate stromal cells to androgen. In Vitro Cell Dev Biol Anim. 30A:745–746. 1994. View Article : Google Scholar : PubMed/NCBI
17	Matsubara A, Yasumoto H and Usui T: Hormone refractory prostate cancer and fibroblast growth factor receptor. Breast Cancer. 6:320–324. 1999. View Article : Google Scholar : PubMed/NCBI
18	Yasumoto H, Matsubara A, Mutaguchi K, Usui T and McKeehan WL: Restoration of fibroblast growth factor receptor 2 suppresses growth and tumorigenicity of malignant human prostate carcinoma PC-3 cells. Prostate. 61:236–242. 2004. View Article : Google Scholar : PubMed/NCBI
19	Matsubara A, Kan M, Feng S and McKeehan WL: Inhibition of growth of malignant rat prostate tumor cells by restoration of fibroblast growth factor receptor 2. Cancer Res. 58:1509–1514. 1998.PubMed/NCBI
20	Feng S, Wang F, Matsubara A, Kan M and McKeehan WL: Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells. Cancer Res. 57:5369–5378. 1997.PubMed/NCBI
21	Polnaszek N, Kwabi-Addo B, Peterson LE, et al: Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res. 63:5754–5760. 2003.PubMed/NCBI
22	Song S, Wientjes MG, Gan Y and Au JL: Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci USA. 97:8658–8663. 2000. View Article : Google Scholar : PubMed/NCBI
23	van Bokhoven A, Varella-Garcia M, Korch C, et al: Molecular characterization of human prostate carcinoma cell lines. Prostate. 57:205–225. 2003.PubMed/NCBI
24	Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF and Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 17:16–23. 1979.PubMed/NCBI
25	Lebedeva IV, Sarkar D, Su ZZ, et al: Bcl-2 and Bcl-x_L differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24. Oncogene. 22:8758–8773. 2003.PubMed/NCBI
26	Liu S, Bishop WR and Liu M: Differential effects of cell cycle regulatory protein p21^WAF1/Cip1 on apoptosis and sensitivity to cancer chemotherapy. Drug Resist Updat. 6:183–195. 2003. View Article : Google Scholar : PubMed/NCBI
27	Matsubara A, Teishima J, Mirkhat S, et al: Restoration of FGF receptor type 2 enhances radiosensitivity of hormone-refractory human prostate carcinoma PC-3 cells. Anticancer Res. 28:2141–2146. 2008.PubMed/NCBI
28	Iwatsuki M, Mimori K, Yokobori T, et al: Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 101:293–299. 2010. View Article : Google Scholar : PubMed/NCBI
29	Yang H, Li LW, Shi M, et al: In vivo study of breast carcinoma radiosensitization by targeting eIF4E. Biochem Biophys Res Commun. 423:878–883. 2012. View Article : Google Scholar : PubMed/NCBI
30	Pienta KJ: Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin Oncol. 28:3–7. 2001. View Article : Google Scholar : PubMed/NCBI
31	Mahon KL, Henshall SM, Sutherland RL and Horvath LG: Pathways of chemotherapy resistance in castration-resistant prostate cancer. Endocr Relat Cancer. 18:R103–R123. 2011. View Article : Google Scholar : PubMed/NCBI
32	Ren J, Chen Y, Song H, Chen L and Wang R: Inhibition of ZEB1 reverses EMT and chemoresistance in docetaxel-resistant human lung adenocarcinoma cell line. J Cell Biochem. 114:1395–1403. 2013. View Article : Google Scholar : PubMed/NCBI
33	Chiou SK, Jones MK and Tarnawski AS: Survivin - an anti-apoptosis protein: its biological roles and implications for cancer and beyond. Med Sci Monit. 9:PI25–PI29. 2003.PubMed/NCBI
34	Rahman KM, Banerjee S, Ali S, et al: 3,3′-Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation. Cancer Res. 69:4468–4475. 2009.
35	Hayashi N, Asano K, Suzuki H, et al: Adenoviral infection of survivin antisense sensitizes prostate cancer cells to etoposide in vivo. Prostate. 65:10–19. 2005. View Article : Google Scholar : PubMed/NCBI
36	Zhang M, Mukherjee N, Bermudez RS, et al: Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo. Prostate. 64:293–302. 2005. View Article : Google Scholar
37	Nomura T, Mimata H, Takeuchi Y, Yamamoto H, Miyamoto E and Nomura Y: The X-linked inhibitor of apoptosis protein inhibits taxol-induced apoptosis in LNCaP cells. Urol Res. 31:37–44. 2003.PubMed/NCBI
38	Amantana A, London CA, Iversen PL and Devi GR: X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol Cancer Ther. 3:699–707. 2004.